Many of Pfizer’s phase 1 clinical trials take place at the Pfizer Clinical Research Unit (PCRU) in Brussels. The participants in these clinical trials commonly don’t have the disease or condition that will later be studied. That’s why the participants are called “healthy volunteers”.
Healthy volunteers in these clinical trials help us understand how a study drug affects the body before patients with the condition are included. This is one way to assess a study drug’s safety before giving it to those who have a medical condition.
Healthy volunteers truly make a difference as we strive for breakthroughs that change patients’ lives. If you’re interested in participating, take a look at the PCRU’s ongoing clinical trials below.
Interested in participating? View our research unit’s clinical trials.
For more information about safe travel, click here.
A look inside our facility
Our clinical research unit is a modern facility that provides study-related clinical care and monitoring of the participants in our clinical trials. The Brussels Clinical Research Unit has 72 inpatient beds as well as outpatient facilities. Many of the studies include overnight stays. Within the research unit location, you’ll have access to internet, a large relaxation and reading area, and a multi-media room for entertainment and games.
Participants receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.
Frequently asked questions
What is the screening visit?
The screening visit is a key step to joining a clinical trial. At this visit, you will review the informed consent document with members of the study team at the PCRU. The informed consent document describes the details of the clinical trial, including what your rights and responsibilities would be as a participant, and any potential risks, so that you can decide whether you’d like to participate. The study team will answer any questions you may have.
If you decide to participate, you will sign the informed consent document and then undergo study-required tests, procedures, or assessments to confirm whether you meet the eligibility criteria for the study. These may include blood tests, an electrocardiogram (a test that uses sensors attached to the skin to check your heart’s rhythm and electrical activity), and vital signs.
Can you describe a typical day for a clinical trial participant at the PCRU facility in Brussels?
A typical clinical trial at the Brussels PCRU may have busy days with lots of study procedures, as well as rest days with lots of downtime.
For a typical clinical trial at this facility, your busy day will likely start with an overnight fast. You’ll likely wake up early in the morning for pre-dose activities, which could include an electrocardiogram (a test that uses sensors attached to the skin to check your heart’s rhythm and electrical activity), vital signs, and a blood draw. The study doctor will review your results to confirm you may receive the study drug. Staff will administer your dose according to the study requirements – it could be a tablet or capsule by mouth, a liquid that you drink, an injection, a treatment applied to the skin, or other forms. After that, you’ll likely have procedures throughout the day and into the evening, such as blood draws and safety assessments, meals, and monitoring by the staff to see how you’re feeling.
On rest days, you might have a few morning procedures, but when you are not busy with study activities, you can enjoy free time within the PCRU. Within the research unit location, you’ll have access to internet, a large relaxation and reading area, and a multi-media room for entertainment and games.
Will I have to stay at the PCRU facility the entire time that I’m participating in the clinical trial?
Each clinical study has its own requirements, so the answer to this depends on the study you are participating in. A participant may be required to stay overnight at the PCRU in Brussels for observation and study procedures. These details are provided in the informed consent document. You may also ask the study team any questions you may have.
Will I be compensated for participating in a clinical trial at the PCRU?
Participants in clinical trials at the PCRU receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.
What precautions are you taking at the facility in response to the COVID-19 pandemic?
Additional measures have been implemented to protect our clinical trial participants and our team from COVID-19. You will have a temperature check and rapid response COVID-19 test upon entry into our facility. We’ve also implemented mandatory mask use and signage to support physical distancing requirements in the PCRU. The unit has staffing at all hours and days of the week to clean and sanitize the facility. Click Learn More for more information on the precautions being taken, along with instructions about how to properly wear a mask.
The eligibility criteria for studies at the PCRU include body mass index (BMI). How can I calculate my BMI?
Body mass index (BMI) is a value to measure the body mass of an adult.
BMI = Body mass in kilograms divided by body height (squared)
For example, for an adult male weighing 93 kg and measuring 1,72 m :
93 kg / (1,72 m x 1,72 m) = 31,4
A BMI between 18,5 and 24,9 corresponds to a normal weight.
The U.S. Centers for Disease Control & Prevention (CDC) also provides a calculator that uses your height and weight to determine your BMI. To calculate your BMI, click Learn More.
Chronic myeloid leukemia is a type of cancer that starts in certain blood-forming cells of the bone marrow.
The objective of the study is to determine if healthy female participants of reproductive age can correctly prepare, activate and administer the medical device into a simulation injection pad after reading the updated Instructions for Use.
The Pfizer Clinical Research Unit of Brussels will be conducting research studies in the near future with participants who are surgically sterilized or menopaused.
Inflammatory bowel disease
A medical device containing 104 mg MPA (medroxyprogesterone acetate) in 0.65 mL suspension for injection is a marketed product in Belgium and is indicated for long-term female contraception via SC injection into the anterior thigh or abdomen every 13 weeks.
In this study the medication will be administrated subcutaneously (under the skin) in one of the following locations: arms, thigh or abdomen. During a subcutaneous injection, a needle is inserted under the skin, rather than into a vein.
How you can help medicine move forward
Pfizer Clinical Research Unit, Route de Lennik 808
1070 Anderlecht, Belgium
Monday-Friday 07:30 am – 05:15 pm
Tel +32 2 556 70 11
Fax +32 2 556 70 15
p/a Jessa Ziekenhuis Salvatorstraat 20
3500 Hasselt, Belgium